Ultrasound therapy for deep infiltrating endometriosis continues to be evaluated in EDAP TMS’s Phase III trial, despite the interim data indicating that the three-month follow-up period was too short to meet the primary endpoint. This French device company has released interim results from its robotic high-intensity focused ultrasound (HIFU) therapy, revealing that the primary endpoint of reduced acute pelvic pain was not achieved in the HIFU treatment arm compared to the Sham treatment arm.
EDAP attributed the failure to meet the primary endpoint to the insufficient duration of the three-month follow-up period, which was deemed too short to show a significantly meaningful difference in pain scores. Ryan Rhodes, EDAP’s chief executive officer, commented: “Although this initial data shows similar levels of improvement in pelvic pain scores between the two arms, we believe that a therapeutic benefit favoring robotic HIFU is more likely to be confirmed over a longer period post-procedure, as suggested by the stabilization of pain scores at six and twelve months observed in the Phase II study.”
Ultrasound Therapy Shows Promising Results in Reducing Pelvic Pain and Endometriosis Nodule Volume
Despite not meeting the primary endpoint, the HIFU treatment demonstrated a significant reduction in pelvic pain scores three months from baseline, as measured by the Visual Analog Scale (VAS). Additionally, patients in the HIFU treatment arm experienced higher volume reductions in the endometriosis nodule compared to those in the Sham treatment arm, as measured using MRI. EDAP plans to provide further updates on the trial later this year.
Deep infiltrating endometriosis is a severe form of endometriosis where uterine tissue grows deep within pelvic organs, causing severe pelvic pain, pain during urination, sex, and menstrual periods. According to the World Health Organization (WHO), endometriosis affects about 10% of reproductive-aged women and girls globally. EDAP’s robotic HIFU therapy offers a non-invasive ablation procedure that uses a high-intensity ultrasound probe to deliver tissue devitalization through acoustic cavitation and thermal ablation. In March 2024, this device received a breakthrough device designation from the US Food and Drug Administration (FDA).
The interim results of the Phase III trial highlight the challenges in demonstrating the efficacy of new therapeutic interventions within a limited follow-up period. The three-month duration was insufficient to show the full therapeutic benefits of the HIFU treatment. However, the significant reductions in pelvic pain and endometriosis nodule volume suggest that longer-term follow-up may provide more conclusive evidence of the treatment’s effectiveness.
Ultrasound Therapy Findings Highlight Need for Longer Follow-Up in Clinical Trials
The importance of continued evaluation and longer follow-up periods in clinical trials is underscored by these findings. The stabilization of pain scores at six and twelve months, as observed in the Phase II study, indicates that the full therapeutic benefits of HIFU therapy may take longer to manifest. EDAP’s commitment to continuing the trial and providing further updates demonstrates its dedication to finding effective non-invasive treatments for endometriosis.
EDAP’s robotic HIFU therapy represents a significant advancement in the treatment of deep infiltrating endometriosis, offering a non-invasive option for patients suffering from severe pelvic pain. The use of high-intensity focused ultrasound allows for precise targeting and ablation of affected tissues, potentially reducing the need for more invasive surgical procedures. The interim data, although not meeting the primary endpoint, provide valuable insights into the potential benefits and limitations of this innovative therapy.
As the trial progresses, longer-term data will be crucial in determining the overall efficacy and safety of the HIFU treatment. The continued monitoring and analysis of patient outcomes will help to refine the therapeutic approach and potentially expand the treatment options available for endometriosis. The forthcoming updates later this year are anticipated to shed more light on the long-term benefits and effectiveness of EDAP’s HIFU therapy.
In conclusion, while the interim Phase III data did not meet the primary endpoint, the findings support the potential of EDAP’s high-intensity ultrasound therapy in treating deep infiltrating endometriosis. The trial underscores the importance of extended follow-up periods in clinical research to fully understand the impact of new treatments. EDAP’s ongoing efforts to advance this non-invasive therapy highlight its commitment to improving the lives of women affected by endometriosis and addressing a significant unmet medical need.
Resource: Medical Device Network, July 22, 2024
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
